{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:35:11Z","timestamp":1782484511638,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"crossref","award":["206643"],"award-info":[{"award-number":["206643"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004590","name":"Helse Midt-Norge","doi-asserted-by":"crossref","award":["90061000"],"award-info":[{"award-number":["90061000"]}],"id":[{"id":"10.13039\/501100004590","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"crossref","award":["223255"],"award-info":[{"award-number":["223255"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is an incurable cancer of terminally differentiated plasma cells that proliferate in the bone marrow. miRNAs are promising biomarkers for risk stratification in MM and several miRNAs are shown to have a function in disease pathogenesis. However, to date, surprisingly few miRNA-mRNA interactions have been described for and functionally validated in MM. In this study, we performed miRNA-seq and mRNA-seq on CD138\u2009+\u2009cells isolated from bone marrow aspirates of 86 MM patients to identify novel interactions between sRNAs and mRNAs. We detected 9.8% significantly correlated miRNA-mRNA pairs of which 5.17% were positively correlated and 4.65% were negatively correlated. We found that miRNA-mRNA pairs that were predicted by in silico target-prediction algorithms were more negatively correlated than non-target pairs, indicating functional miRNA targeting and that correlation between miRNAs and mRNAs from patients can be used to identify miRNA-targets. mRNAs for negatively correlated miRNA-mRNA target pairs were associated with gene ontology terms such as autophagy, protein degradation and endoplasmic stress response, reflecting important processes in MM. Targets for two specific miRNAs, miR-125b-5p and miR-365b-3p, were functionally validated in MM cell line transfection experiments followed by RNA-sequencing and qPCR. In summary, we identified functional miRNA-mRNA target pairs by correlating miRNA and mRNA data from primary MM cells. We identified several target pairs that are of potential interest for further studies. The data presented here may serve as a hypothesis-generating knowledge base for other researchers in the miRNA\/MM field. We also provide an interactive web application that can be used to exploit the miRNA-target interactions as well as clinical parameters associated to these target-pairs.<\/jats:p>","DOI":"10.1038\/s41598-022-16448-0","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:08:09Z","timestamp":1657904889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma"],"prefix":"10.1038","volume":"12","author":[{"given":"Kristin Roseth","family":"Aass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonje Marie Vikene","family":"Nedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synne Stokke","family":"Tryggestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Hauk\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias S.","family":"Sl\u00f8rdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Waage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Standal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Mjelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"issue":"2","key":"16448_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281\u2013297 (2004).","journal-title":"Cell"},{"issue":"1","key":"16448_CR2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","volume":"19","author":"RC Friedman","year":"2009","unstructured":"Friedman, R. C., Farh, K. K., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19(1), 92\u2013105 (2009).","journal-title":"Genome Res."},{"issue":"6","key":"16448_CR3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt.1543","volume":"27","author":"AA Khan","year":"2009","unstructured":"Khan, A. A. et al. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol. 27(6), 549\u2013555 (2009).","journal-title":"Nat Biotechnol."},{"issue":"3","key":"16448_CR4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2009.274","volume":"24","author":"NC Gutierrez","year":"2010","unstructured":"Gutierrez, N. C. et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 24(3), 629\u2013637 (2010).","journal-title":"Leukemia"},{"issue":"1","key":"16448_CR5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41467-018-07981-6","volume":"10","author":"N Wang","year":"2019","unstructured":"Wang, N. et al. Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation. Nat Commun. 10(1), 95 (2019).","journal-title":"Nat Commun."},{"issue":"1","key":"16448_CR6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2011.05.017","volume":"309","author":"L Chen","year":"2011","unstructured":"Chen, L. et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett. 309(1), 62\u201370 (2011).","journal-title":"Cancer Lett."},{"issue":"2","key":"16448_CR7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.18632\/oncotarget.820","volume":"4","author":"MT Di Martino","year":"2013","unstructured":"Di Martino, M. T. et al. In vitro and in vivo anti-tumor activity of miR-221\/222 inhibitors in multiple myeloma. Oncotarget 4(2), 242\u2013255 (2013).","journal-title":"Oncotarget"},{"issue":"35","key":"16448_CR8","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","volume":"105","author":"F Pichiorri","year":"2008","unstructured":"Pichiorri, F. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 105(35), 12885\u201312890 (2008).","journal-title":"Proc Natl Acad Sci USA."},{"issue":"11","key":"16448_CR9","doi-asserted-by":"crossref","first-page":"e79752","DOI":"10.1371\/journal.pone.0079752","volume":"8","author":"S Xu","year":"2013","unstructured":"Xu, S. et al. Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS ONE 8(11), e79752 (2013).","journal-title":"PLoS ONE"},{"issue":"2","key":"16448_CR10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/carcin\/bgs333","volume":"34","author":"CY Sun","year":"2013","unstructured":"Sun, C. Y. et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 34(2), 426\u2013435 (2013).","journal-title":"Carcinogenesis"},{"issue":"10","key":"16448_CR11","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1078-0432.CCR-14-1437","volume":"21","author":"Y Yang","year":"2015","unstructured":"Yang, Y. et al. miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res. 21(10), 2399\u20132411 (2015).","journal-title":"Clin Cancer Res."},{"issue":"11","key":"16448_CR12","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/cancers11111738","volume":"11","author":"H Handa","year":"2019","unstructured":"Handa, H., Murakami, Y., Ishihara, R., Kimura-Masuda, K. & Masuda, Y. The role and function of microRNA in the pathogenesis of multiple myeloma. Cancers 11(11), 1738 (2019).","journal-title":"Cancers"},{"issue":"1","key":"16448_CR13","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1038\/s41598-021-90424-y","volume":"11","author":"A Katiyar","year":"2021","unstructured":"Katiyar, A. et al. Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data. Sci Rep. 11(1), 10957 (2021).","journal-title":"Sci Rep."},{"key":"16448_CR14","doi-asserted-by":"crossref","unstructured":"Misiewicz-Krzeminska I, Krzeminski P, Corchete LA, Quwaider D, Rojas EA, Herrero AB, et al. Factors regulating microRNA expression and function in multiple myeloma. Noncoding RNA. 2019;5(1).","DOI":"10.3390\/ncrna5010009"},{"issue":"1","key":"16448_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","volume":"120","author":"BP Lewis","year":"2005","unstructured":"Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1), 15\u201320 (2005).","journal-title":"Cell"},{"issue":"D1","key":"16448_CR16","doi-asserted-by":"crossref","first-page":"D127","DOI":"10.1093\/nar\/gkz757","volume":"48","author":"Y Chen","year":"2020","unstructured":"Chen, Y. & Wang, X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 48(D1), D127\u2013D131 (2020).","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"16448_CR17","first-page":"8487","volume":"10","author":"Y Jiang","year":"2017","unstructured":"Jiang, Y., Luan, Y., He, D. & Chen, G. miR-125b expression affects tumor growth of multiple myeloma via targeting MKK7. Int J Clin Exp Pathol. 10(8), 8487\u20138494 (2017).","journal-title":"Int J Clin Exp Pathol."},{"issue":"11","key":"16448_CR18","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3109\/10428190903221010","volume":"50","author":"K Unno","year":"2009","unstructured":"Unno, K., Zhou, Y., Zimmerman, T., Platanias, L. C. & Wickrema, A. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma. 50(11), 1865\u20131871 (2009).","journal-title":"Leuk Lymphoma."},{"key":"16448_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fgene.2014.00023","volume":"5","author":"S Peterson","year":"2014","unstructured":"Peterson, S. et al. Common features of microRNA target prediction tools. Front. Genet. 5, 23 (2014).","journal-title":"Front. Genet."},{"issue":"36","key":"16448_CR20","doi-asserted-by":"crossref","first-page":"39165","DOI":"10.18632\/oncotarget.5381","volume":"6","author":"A Seckinger","year":"2015","unstructured":"Seckinger, A. et al. miRNAs in multiple myeloma: a survival relevant complex regulator of gene expression. Oncotarget 6(36), 39165\u201339183 (2015).","journal-title":"Oncotarget"},{"issue":"47","key":"16448_CR21","doi-asserted-by":"crossref","first-page":"19160","DOI":"10.1073\/pnas.1316991110","volume":"110","author":"S Zadran","year":"2013","unstructured":"Zadran, S., Remacle, F. & Levine, R. D. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc Natl Acad Sci USA. 110(47), 19160\u201319165 (2013).","journal-title":"Proc Natl Acad Sci USA."},{"key":"16448_CR22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ebiom.2019.03.082","volume":"43","author":"H Tan","year":"2019","unstructured":"Tan, H. et al. Pan-cancer analysis on microRNA-associated gene activation. EBioMedicine 43, 82\u201397 (2019).","journal-title":"EBioMedicine"},{"issue":"6","key":"16448_CR23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/1535-7163.MCT-12-0782","volume":"12","author":"L Vincenz","year":"2013","unstructured":"Vincenz, L., Jager, R., O\u2019Dwyer, M. & Samali, A. Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma. Mol Cancer Ther. 12(6), 831\u2013843 (2013).","journal-title":"Mol Cancer Ther."},{"issue":"12","key":"16448_CR24","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107(12), 4907\u20134916 (2006).","journal-title":"Blood"},{"issue":"43","key":"16448_CR25","doi-asserted-by":"crossref","first-page":"70845","DOI":"10.18632\/oncotarget.12226","volume":"7","author":"K Baranowska","year":"2016","unstructured":"Baranowska, K. et al. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. Oncotarget 7(43), 70845\u201370856 (2016).","journal-title":"Oncotarget"},{"issue":"8","key":"16448_CR26","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl, D. T. et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy 10(8), 1380\u20131390 (2014).","journal-title":"Autophagy"},{"issue":"5755","key":"16448_CR27","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1126\/science.1121158","volume":"310","author":"KK Farh","year":"2005","unstructured":"Farh, K. K. et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310(5755), 1817\u20131821 (2005).","journal-title":"Science"},{"issue":"1","key":"16448_CR28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/emboj\/18.1.270","volume":"18","author":"S Pyronnet","year":"1999","unstructured":"Pyronnet, S. et al. Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E. EMBO J. 18(1), 270\u2013279 (1999).","journal-title":"EMBO J."},{"issue":"4","key":"16448_CR29","doi-asserted-by":"crossref","first-page":"e94011","DOI":"10.1371\/journal.pone.0094011","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi, Y. et al. MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses. PLoS ONE 9(4), e94011 (2014).","journal-title":"PLoS ONE"},{"issue":"2","key":"16448_CR30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/onc.2012.43","volume":"32","author":"Y Shi","year":"2013","unstructured":"Shi, Y. et al. MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells. Oncogene 32(2), 190\u2013197 (2013).","journal-title":"Oncogene"},{"key":"16448_CR31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2021.02.084","volume":"556","author":"J Wang","year":"2021","unstructured":"Wang, J., Da, C., Su, Y., Song, R. & Bai, Z. MKNK2 enhances chemoresistance of ovarian cancer by suppressing autophagy via miR-125b. Biochem. Biophys. Res. Commun. 556, 31\u201338 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"16448_CR32","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1158\/0008-5472.CAN-10-2435","volume":"71","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 71(10), 3552\u20133562 (2011).","journal-title":"Cancer Res."},{"issue":"8","key":"16448_CR33","doi-asserted-by":"crossref","first-page":"e72829","DOI":"10.1371\/journal.pone.0072829","volume":"8","author":"S Pan","year":"2013","unstructured":"Pan, S. et al. ERManI is a target of miR-125b and promotes transformation phenotypes in hepatocellular carcinoma (HCC). PLoS ONE 8(8), e72829 (2013).","journal-title":"PLoS ONE"},{"issue":"6","key":"16448_CR34","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jid.2016.02.803","volume":"136","author":"F Rambow","year":"2016","unstructured":"Rambow, F. et al. Regulation of melanoma progression through the TCF4\/miR-125b\/NEDD9 cascade. J Invest Dermatol. 136(6), 1229\u20131237 (2016).","journal-title":"J Invest Dermatol."},{"key":"16448_CR35","doi-asserted-by":"crossref","unstructured":"Cheung R, Pizza G, Chabosseau P, Rolando D, Tomas A, Burgoyne T, et al. Glucose-dependent miR-125b is a negative regulator of \u03b2-cell function. bioRxiv. 2021:2021.05.17.444559.","DOI":"10.1101\/2021.05.17.444559"},{"issue":"5","key":"16448_CR36","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.molcel.2020.06.028","volume":"79","author":"R Sebastian","year":"2020","unstructured":"Sebastian, R. et al. Epigenetic regulation of DNA repair pathway choice by MacroH2A1 splice variants ensures genome stability. Mol. Cell 79(5), 836\u201345.e7 (2020).","journal-title":"Mol. Cell"},{"issue":"8","key":"16448_CR37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41419-021-04036-5","volume":"12","author":"C Yoon","year":"2021","unstructured":"Yoon, C., Lu, J., Ryeom, S. W., Simon, M. C. & Yoon, S. S. PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance. Cell Death Dis. 12(8), 749 (2021).","journal-title":"Cell Death Dis."},{"issue":"1","key":"16448_CR38","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1038\/ncomms7380","volume":"6","author":"B Chang","year":"2015","unstructured":"Chang, B. et al. Epsin is required for Dishevelled stability and Wnt signalling activation in colon cancer development. Nat. Commun. 6(1), 6380 (2015).","journal-title":"Nat. Commun."},{"issue":"1","key":"16448_CR39","doi-asserted-by":"crossref","first-page":"14058","DOI":"10.1038\/ncomms14058","volume":"8","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. VGLL4 targets a TCF4\u2013TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer. Nat. Commun. 8(1), 14058 (2017).","journal-title":"Nat. Commun."},{"issue":"5","key":"16448_CR40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel, H., Kocemba, K. A., Spaargaren, M. & Pals, S. T. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia 33(5), 1063\u20131075 (2019).","journal-title":"Leukemia"},{"issue":"4","key":"16448_CR41","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3892\/or.2017.5458","volume":"37","author":"Y Zhu","year":"2017","unstructured":"Zhu, Y., Zhao, H., Rao, M. & Xu, S. MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3. Oncol Rep. 37(4), 2185\u20132192 (2017).","journal-title":"Oncol Rep."},{"issue":"1","key":"16448_CR42","first-page":"108","volume":"25","author":"WH Liu","year":"2021","unstructured":"Liu, W. H. et al. LINC00641 regulates prostate cancer cell growth and apoptosis via the miR-365a-3p\/VGLL4 axis. Eur Rev Med Pharmacol Sci. 25(1), 108\u2013115 (2021).","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"27","key":"16448_CR43","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2017010801","volume":"1","author":"M Zahoor","year":"2017","unstructured":"Zahoor, M. et al. Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss. Blood Adv. 1(27), 2656\u20132666 (2017).","journal-title":"Blood Adv."},{"issue":"52","key":"16448_CR44","doi-asserted-by":"crossref","first-page":"90077","DOI":"10.18632\/oncotarget.21412","volume":"8","author":"R Mjelle","year":"2017","unstructured":"Mjelle, R. et al. Identification of metastasis-associated microRNAs in serum from rectal cancer patients. Oncotarget 8(52), 90077\u201390089 (2017).","journal-title":"Oncotarget"},{"key":"16448_CR45","unstructured":"Andrews S. FastQC: a quality control tool for high throughput sequence data. 2019 Available from: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"issue":"1","key":"16448_CR46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1), 15\u201321 (2013).","journal-title":"Bioinformatics"},{"issue":"2","key":"16448_CR47","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15(2), R29 (2014).","journal-title":"Genome Biol."},{"key":"16448_CR48","doi-asserted-by":"crossref","unstructured":"Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 2019.","DOI":"10.1093\/nar\/gkz896"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16448-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16448-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16448-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:27:02Z","timestamp":1673623622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16448-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16448"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16448-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12147"}}